INK4a/ARF mutations accelerate lymphomagenesis and promote chemoresistance by disabling p53. - Wikidata - awgldk - TriplyDB

INK4a/ARF mutations accelerate lymphomagenesis and promote chemoresistance by disabling p53.

INK4a/ARF mutations accelerate lymphomagenesis and promote chemoresistance by disabling p53.

http://www.wikidata.org/entity/Q35208402

about

TBX-3, the gene mutated in Ulnar-Mammary Syndrome, is a negative regulator of p19ARF and inhibits senescence Adenovirus-mediated overexpression of p14(ARF) induces p53 and Bax-independent apoptosis The novel ETS factor TEL2 cooperates with Myc in B lymphomagenesis Targeting of C-terminal binding protein (CtBP) by ARF results in p53-independent apoptosis.Suppression of tumorigenesis by the p53 target PUMA p53-independent functions of the p19(ARF) tumor suppressor c-Myc augments gamma irradiation-induced apoptosis by suppressing Bcl-XL Developmental context determines latency of MYC-induced tumorigenesis p19Arf suppresses growth, progression, and metastasis of Hras-driven carcinomas through p53-dependent and -independent pathways MYC activation is a hallmark of cancer initiation and maintenance Animal models of leukemia: any closer to the real thing?Quantitative proteomic analysis of myc-induced apoptosis: a direct role for Myc induction of the mitochondrial chloride ion channel, mtCLIC/CLIC4 Induction and apoptotic regression of lung adenocarcinomas by regulation of a K-Ras transgene in the presence and absence of tumor suppressor genes Bax loss impairs Myc-induced apoptosis and circumvents the selection of p53 mutations during Myc-mediated lymphomagenesis Apoptosis triggered by Myc-induced suppression of Bcl-X(L) or Bcl-2 is bypassed during lymphomagenesis p53 status dictates responses of B lymphomas to monotherapy with proteasome inhibitors Topoisomerase levels determine chemotherapy responsein vitroandin vivo The epigenetic modifier JMJD6 is amplified in mammary tumors and cooperates with c-Myc to enhance cellular transformation, tumor progression, and metastasis Mutant p53 Protein and the Hippo Transducers YAP and TAZ: A Critical Oncogenic Node in Human Cancers.Targeting lysosomal degradation induces p53-dependent cell death and prevents cancer in mouse models of lymphomagenesis Disruption of the ARF transcriptional activator DMP1 facilitates cell immortalization, Ras transformation, and tumorigenesis.Limited role of murine ATM in oncogene-induced senescence and p53-dependent tumor suppression.The siRNA targeted to mdr1b and mdr1a mRNAs in vivo sensitizes murine lymphosarcoma to chemotherapy Myc suppression of Nfkb2 accelerates lymphomagenesis.Functional identification of tumor-suppressor genes through an in vivo RNA interference screen in a mouse lymphoma model Phosphorylation of p53 serine 18 upregulates apoptosis to suppress Myc-induced tumorigenesis Mouse models of cancer as biological filters for complex genomic data.Inactivation of MYC reverses tumorigenesis.Apoptosis in cancer.BET and HDAC inhibitors induce similar genes and biological effects and synergize to kill in Myc-induced murine lymphoma Origin of chromosomal translocations in lymphoid cancer.Loss of p73 promotes dissemination of Myc-induced B cell lymphomas in mice A deficiency in Mdm2 binding protein inhibits Myc-induced B-cell proliferation and lymphomagenesis.The c-Myc transactivation domain is a direct modulator of apoptotic versus proliferative signals.Intratumor heterogeneity alters most effective drugs in designed combinations.IRF4 is a suppressor of c-Myc induced B cell leukemia.p53-dependent senescence delays Emu-myc-induced B-cell lymphomagenesis.Dial 9-1-1 for p53: mechanisms of p53 activation by cellular stress In vivo analysis of p53 tumor suppressor function using genetically engineered mouse models Dynamics of ARF regulation that control senescence and cancer.

P2860

Q24292042-1CFF0F68-9F04-4F6E-A646-425B4883C838 Q24300313-B0727EC5-26DD-4CC8-944C-C00E979FEABC Q24519077-2875DB1A-12C5-4F30-93C0-22E159DE7346 Q24548025-E71891EA-80BC-4A7F-9695-52623066A323 Q24563144-7E0FE938-7AC8-4614-8178-A306D260616F Q24600863-96B4F011-5DFE-48A0-A527-EDD8F3AB0DCD Q24653312-5FF0F397-F55E-475D-9721-F40D611077F9 Q24794847-29E3A907-E579-4AF1-8419-36F0B414396A Q24799059-29CADE90-2976-4EF5-B213-BF3AF8292028 Q27026026-7CBC76B1-0B44-4985-8413-8D841FCEB003 Q27026520-2A61CB40-7024-4D0C-A2EA-B4EDF0FDC62B Q28284332-8B6F1B27-0B2A-4849-9E2E-04CC7A7DE971 Q28343950-BF67DD28-F164-4D7D-920B-1BA328CB6CE3 Q28513038-3E33DBBA-E4D6-4A6A-9D79-D117AA301495 Q28593886-7D4F8623-52F0-41E5-A2C5-FD652A443DC2 Q28757630-1CA1530C-B60F-4BA5-A604-BFD5425281D9 Q29395563-EFC720A2-FB17-40E0-8A1E-8B383107B73F Q29544441-D5CE4251-9B5C-4CE1-8D60-41937A46BB8C Q30354662-7A7FCE3E-2320-4DD6-8E07-9FD09248E48A Q30480882-4B7FD10B-444E-4A37-BC90-37934CD9844B Q30886165-C7A3F4AC-E159-45D5-ACE5-4E483ACE15E3 Q33440643-082AC38C-F7F2-4590-968C-193FBF039CA6 Q33578222-C1FD5FCD-9E1C-48D8-BF9C-2E88EEDC524D Q33624136-41FFACF2-AB25-49B7-B155-CD9419134ABE Q33693027-8700580D-5B1A-497B-A0C0-B0D180095557 Q33693493-F07587D1-CDB8-431A-ABC4-ACA5EDB6C549 Q33704756-003B2D87-F9CB-49F5-8415-E407BD5509BF Q33784668-C38B2A46-8CE5-40E6-BC23-8BE731B678AA Q33846227-B093076A-C49D-4989-AA14-F54855DC1584 Q33853887-4B1D2B05-6E4A-4706-822C-105EE3BE520E Q33870612-058A72BF-2137-42A8-B5A1-56F94A90FBA8 Q33882866-7F55F37A-453B-49FF-8A12-1304EC0B8577 Q33893827-0C5D93BD-4E19-4C93-90F5-95FD2E4083D4 Q33963949-47DA35A9-AA55-48A3-9342-AA1831C83C2F Q33972115-16084DD4-42C0-454C-98D1-11CA4E053CD8 Q33983307-F55075AB-DA1A-4FE7-8D47-B11D4003C3A1 Q33991429-207C695D-5F70-4808-B3FB-2E7E656FA52F Q33997846-7C292354-8D5C-4897-95F9-680059555CF8 Q34042319-99440B7E-CB85-4C1B-9E33-D12224135499 Q34047232-3887A382-0EE0-4C87-A362-0F73E75C494F

P2860

INK4a/ARF mutations accelerate lymphomagenesis and promote chemoresistance by disabling p53.

http://www.wikidata.org/entity/Q35208402

description

1999 nî lūn-bûn

@nan

1999 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

1999 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

1999年の論文

@ja

1999年論文

@yue

1999年論文

@zh-hant

1999年論文

@zh-hk

1999年論文

@zh-mo

1999年論文

@zh-tw

1999年论文

@wuu

name

INK4a/ARF mutations accelerate ...... moresistance by disabling p53.

@ast

INK4a/ARF mutations accelerate ...... moresistance by disabling p53.

@en

type

label

INK4a/ARF mutations accelerate ...... moresistance by disabling p53.

@ast

INK4a/ARF mutations accelerate ...... moresistance by disabling p53.

@en

prefLabel

INK4a/ARF mutations accelerate ...... moresistance by disabling p53.

@ast

INK4a/ARF mutations accelerate ...... moresistance by disabling p53.

@en

P1433

Q35208402-DBEDC656-629D-4FEE-ABB6-8EF70F9D9A2B

P1476

Q35208402-FD1155EA-C770-4CDE-B653-12FCDB14D206

P2093

Q35208402-241FF962-FD47-4746-B570-6799AAFD9B7C

Q35208402-340C89F5-D12E-491F-9DCE-25A40E090FD5

Q35208402-671D9CAA-DA60-47BB-81FD-1A8FAC342750

Q35208402-AB6370DF-A0D4-4437-8823-A1550C942A66

Q35208402-D178A8F5-F4B8-4443-B5C3-53D1CA22DB82

P2860

Q35208402-1922F2C5-51A4-4DDB-A2C6-8A2C9BF0E5BC

Q35208402-20269A47-34BC-4774-A9A9-4D60474332B9

Q35208402-2B1EADEE-1D46-4AC5-9656-9DFA3A9D111C

Q35208402-2E2D8399-0615-4958-ACD6-1DE25F607920

Q35208402-2E58EE27-70FD-400A-B87B-B76061F11FBD

Q35208402-45B0E6D0-FE26-491C-88C8-5C7A066DE42B

Q35208402-4B79C0D4-2BEB-450F-AB4C-42501B2AC6D6

Q35208402-4D114F7A-92BF-45F9-89CD-4C5388F99616

Q35208402-4E41E94E-2EA6-48B8-8E5D-C4942241F7D1

Q35208402-52D1643B-275E-4C2C-94B0-CBB07A957D54

P304

Q35208402-8D3E9726-9409-4540-8C94-1A41D5E62A4A

P31

Q35208402-1C1D47EB-4A4F-47A0-967B-118798DA11CA

P356

Q35208402-9018F740-3D01-4FBA-9AF0-00A7B973340A

P433

Q35208402-238A1EF6-0E9E-4F0D-A58F-2D6265E60B7F

P478

Q35208402-1F210BC8-FD46-4A20-9BDE-BD5FCCFA343C

P577

Q35208402-AD36D6B8-F15B-49E5-8DFA-108B3F06CA80

P5875

Q35208402-E2EFB93E-C81E-4E4D-ADC9-9AF322E29A75

P698

Q35208402-4C978F61-864F-463C-9761-7B71B91929CE

P932

Q35208402-AF0989BA-483F-4E2F-8DD2-3779C91C1678

P356

P1433

Genes & Development

P1476

INK4a/ARF mutations accelerate ...... moresistance by disabling p53.

@en

P2093

C A Schmitt

http://www.w3.org/2001/XMLSchema#string

E de Stanchina

http://www.w3.org/2001/XMLSchema#string

M E McCurrach

http://www.w3.org/2001/XMLSchema#string

R R Wallace-Brodeur

http://www.w3.org/2001/XMLSchema#string

S W Lowe

http://www.w3.org/2001/XMLSchema#string

P2860

Mutations in human ARF exon 2 disrupt its nucleolar localization and impair its ability to block nuclear export of MDM2 and p53

ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways

A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4

Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a

P19(ARF) stabilizes p53 by blocking nucleo-cytoplasmic shuttling of Mdm2

p53 gene mutation in B-cell chronic lymphocytic leukemia is associated with drug resistance and is independent of MDR1/MDR3 gene expression.

The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53

The complexity of p53 modulation: emerging patterns from divergent signals

Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization

p53-dependent apoptosis modulates the cytotoxicity of anticancer agents

P304

2670-2677

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1101/GAD.13.20.2670

http://www.w3.org/2001/XMLSchema#string

P433

20

http://www.w3.org/2001/XMLSchema#string

P478

13

http://www.w3.org/2001/XMLSchema#string

P577

1999-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

12758342

http://www.w3.org/2001/XMLSchema#string

P698

10541553

http://www.w3.org/2001/XMLSchema#string

P932

317110

http://www.w3.org/2001/XMLSchema#string